What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2024-11-13 compared with 2024-08-14 · 38 added, 21 removed, 18 unchanged (77% of the section changed)

OTHER INFORMATION

Not applicable .

Manufacturing and Supply Agreement dated as of October 31, 2020 by and between Unicycive Therapeutics, Inc.

and Shilpa Medicare Ltd.

First Amendment to Manufacturing and Supply Agreement dated June 25, 2024 by and between Unicycive Therapeutics, Inc.

and Shilpa Medicare Ltd.

Employment Agreement (this “ Agreement ”), dated August

12, 2024, by and among Unicycive Therapeutics Inc.

and Doug Jermasek.

10b5-1 Trading Plans

three months ended September 30, 2024, no Section 16 officers and directors adopted ,

modified or terminated a “Rule 10b5-1 trading arrangement” (as defined

in Item 408 of Regulation S-K of the Exchange Act), except that on September 20, 2024 , Shalabh Gupta , M.D., our Chief Executive

Officer , adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale

of up to 900,000 shares of our common stock beginning on January 20, 2025 and terminating on January 19, 2026 .

Certificate of Correction

On November 8, 2024, we filed a Certificate of

Correction with the Secretary of State of Delaware (“Certificate of Correction”) for our Certificate of Designation of Preferences,

Rights and Limitations of Series B Convertible Preferred Stock (“Series B Certificate of Designation”) filed with the Secretary

of State of Delaware on March 14, 2024.

The Certificate of Correction was filed to correct certain scrivener’s errors in the Series

B Certificate of Designation with respect to voting rights for the Series B Convertible Preferred Stock under Section 4(a) and conversion

at the option of holder under Section 6(c) thereof.

Specifically, Section 4(a) of the Series B Certificate of Designation inadvertently

stated that the “Voting Conversion Price” be used for determining the as-converted amount of the Series B Convertible Preferred

Stock instead of using the “Conversion Price” for such determination and also failed to reference the limitations imposed

by Section 6(f).

In addition, Section 6(c) of the Series B Certificate of Designation inadvertently used a fixed number of shares of common

stock into which shares of Series B-2 Convertible Preferred Stock convert into (one thousand shares), instead of based on the conversion

rate equal to the Stated Value ($1,000) divided by the Conversion Price ($1.00).

Pursuant to Section 103(f) of the Delaware General Corporation

Law, the correction was effective as of March 14, 2024, except as to those persons who are substantially and adversely affected by the

correction, and as to those persons the correction was effective as of November 8, 2024.

The foregoing description of the Certificate of

Correction is qualified in its entirety by reference to the full text of the Certificate of Correction, which is filed herewith as Exhibit

3.1 and incorporated herein by reference.

Certificate of Correction to Series B Preferred Certificate of Designation filed with the Delaware Secretary of State on November 8, 2024

Certification of Principal Executive Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.

6 unchanged sentences

Inline XBRL Taxonomy Extension Schema Document.

Inline XBRL Taxonomy Extension Calculation Linkbase

Inline XBRL Taxonomy Extension Definition Linkbase

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

Inline XBRL Taxonomy Extension Definition Linkbase Document.

Inline XBRL Taxonomy Extension Label Linkbase Document.

Inline XBRL Taxonomy Extension Presentation Linkbase

Cover Page Interactive Data File (formatted as Inline

XBRL and contained in Exhibit 101).

@ Pursuant to Item 601(b)(10)

of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because

such information is both not material and is the type that the Company treats as private or confidential.

Pursuant to the requirements of Section 13 or

15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned,

thereunto duly authorized on the 14th day of August, 2024.

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because such information is both not material and is the type that the Company treats as private or confidential.

Pursuant to the requirements of Section 13

or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the

undersigned, thereunto duly authorized on the 13th day of November, 2024.

/s/ Shalabh Gupta

Chief Executive Officer, President and Chairman

August 14, 2024

November 13, 2024

Shalabh Gupta

2 unchanged sentences

Chief Financial Officer

August 14, 2024

November 13, 2024

John Townsend

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information